News & Publications

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

  • KemPharm Announces Top Line Results from KP415.E01 Efficacy and Safety Trial in Children With ADHD; KP415 Successfully Meets Primary Efficacy Endpoint

  • KemPharm Announces Positive, Topline Results from an IV Human Abuse Potential Trial with KP415 Prodrug; Reports Q1 2018 Results

  • KemPharm, Inc. to Report First Quarter 2018 Results

  • KemPharm Reports Fourth Quarter and Year End 2017 Results

  • KemPharm, Inc. to Report Fourth Quarter and Year End 2017 Results

  • Positive Topline Results from KP415 PK Study in Children/Adolescents With ADHD

  • KemPharm to Present at Upcoming Investor Conferences

  • KemPharm Announces FDA Approval of Apadaz™

  • MoneyShow Orlando Conference

  • KP415 – APSARD 2018